Payment overview · 2025
General Payments
$1,055.26
48 reported records · 19 companies
Healthcare provider profile · identity verified
Sam Eun Kim, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ODESSA, TX · NPI 1093987885
Verified facts
What the public records show
CMS Open Payments records show Sam Eun Kim, M.D. received $1,055.26 in general payments during 2025 across 48 reported records.
Ardelyx, Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $209.12 | 19.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.43 | 10.8% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $110.53 | 10.5% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $102.82 | 9.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.39 | 9.6% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $56.64 | 5.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.15 | 4.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.04 | 4.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.30 | 3.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.44 | 3.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $31.02 | 2.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.21 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.88 | 2.3% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $23.29 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.02 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.30 | 1.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.85 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.51 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.32 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,055.26 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $209.12 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.43 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.43 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $110.53 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $102.82 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $82.22 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $82.22 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $43.04 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $43.04 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.30 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $31.69 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.44 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $31.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| Clinical Trial Product Normalized: clinical trial product |
Device | Boston Scientific Corporation | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
167 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 804 | 210 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 649 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 402 | 117 |
| Losartan Potassium | Losartan Potassium | 381 | 101 |
| Montelukast Sodium | Montelukast Sodium | 377 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 341 | 92 |
| Azithromycin | Azithromycin | 338 | 214 |
| Methylprednisolone | Methylprednisolone | 333 | 208 |
| Gabapentin | Gabapentin | 309 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 90 |
| Metformin Hcl Er | Metformin Hcl | 280 | 80 |
| Allopurinol | Allopurinol | 261 | 71 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 251 | 138 |
| Trazodone Hcl | Trazodone Hcl | 239 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 68 |
| Potassium Chloride | Potassium Chloride | 217 | 71 |
| Meloxicam | Meloxicam | 201 | 71 |
| Alprazolam | Alprazolam | 183 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 178 | 50 |
| Ezetimibe | Ezetimibe | 173 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 171 | 60 |
| Synthroid | Levothyroxine Sodium | 167 | 39 |
| Lisinopril | Lisinopril | 163 | 46 |
| Eliquis | Apixaban | 158 | 31 |
| Furosemide | Furosemide | 145 | 45 |
| Metformin Hcl | Metformin Hcl | 141 | 43 |
| Omeprazole | Omeprazole | 141 | 36 |
| Simvastatin | Simvastatin | 133 | 38 |
| Jardiance | Empagliflozin | 131 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 37 |
| Januvia | Sitagliptin Phosphate | 118 | 27 |
| Ozempic | Semaglutide | 117 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 11 |
| Carvedilol | Carvedilol | 108 | 35 |
| Sertraline Hcl | Sertraline Hcl | 106 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 35 |
| Tramadol Hcl | Tramadol Hcl | 100 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 98 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 63 |
| Donepezil Hcl | Donepezil Hcl | 96 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 32 |
| Mupirocin | Mupirocin | 88 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 24 |
| Tresiba Flextouch U-200 | Insulin Degludec | 76 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 18 |
| Finasteride | Finasteride | 69 | 20 |
| Clonazepam | Clonazepam | 68 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Sucralfate | Sucralfate | 66 | 31 |
| Valacyclovir | Valacyclovir Hcl | 66 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 62 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 42 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 23 |
| Glipizide Er | Glipizide | 62 | 16 |
| Memantine Hcl | Memantine Hcl | 62 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 21 |
| Celecoxib | Celecoxib | 60 | 16 |
| Myrbetriq | Mirabegron | 59 | 14 |
| Telmisartan | Telmisartan | 56 | 15 |
| Linzess | Linaclotide | 52 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 23 |
| Buspirone Hcl | Buspirone Hcl | 49 | 13 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 14 |
| Glimepiride | Glimepiride | 47 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Irbesartan | Irbesartan | 45 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | 12 |
| Novolog Flexpen | Insulin Aspart | 44 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 13 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 15 |
| Cephalexin | Cephalexin | 41 | 35 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Rybelsus | Semaglutide | 39 | 12 |
| Fluconazole | Fluconazole | 37 | 19 |
| Gemfibrozil | Gemfibrozil | 37 | 12 |
| Glyxambi | Empagliflozin/Linagliptin | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Estradiol | Estradiol | 35 | 13 |
| Levetiracetam | Levetiracetam | 35 | 11 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 21 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 28 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Colchicine | Colchicine | 25 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Clarithromycin | Clarithromycin | 23 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | 13 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Tobramycin | Tobramycin | 15 | 12 |
| Valsartan | Valsartan | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Toprol Xl | Metoprolol Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,055.26 · 48 records | Ardelyx, Inc. | AIRSUPRA, BREZTRI, CREON, Clinical Trial Product, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INSPIRE, Kerendia, LINZESS, Leqembi, MOUNJARO, Ozempic, PROLIA, Rybelsus, TRELEGY ELLIPTA, Tyenne, Tymlos, UBRELVY, VIBERZI, VOQUEZNA, WATCHMAN FLX, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error